Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma

NCT04689659 is registered in ClinicalTrials.gov with Beijing Boren Hospital as lead sponsor.

NCT NCT04689659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04689659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
Lead sponsor
Beijing Boren Hospital
Phase
Phase 2
Overall status
Completed
Start date
December 1, 2021
Completion date
April 3, 2024
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory t lymphoblastic leukemia/lymphoma, relapse/recurrence, t-cell leukemia/lymphoma